We founded Innorna in 2019 on the conviction that mRNA can achieve what existing therapeutic approaches cannot. From day one, we built a proprietary platform from the ground up — a rationally designed lipid library of over 100,000 ionizable lipid structures, extensively screened from synthesis through non-human primate studies, with rigorous design-of-experiments optimization across our targeted LNP delivery systems.

From that foundation, we built fully integrated capabilities spanning discovery, development, and cGMP manufacturing — advancing four drug candidates into clinical trials, dosing more than 900 study participants, and translating platform innovation into clinical-stage programs at a pace and capital efficiency that few companies at our stage can match.

Today, we are expanding from vaccines into mRNA-based protein replacement therapies for chronic metabolic diseases and targeted in vivo immunotherapies for autoimmune conditions. Each program deepens our platform, and each platform advance opens new pipeline possibilities. This is the virtuous cycle at the heart of Innorna.